Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate

Biochemical Pharmacology

Volumn 52, Issue 7, 1996, Pages 1097-1102

  Panasci, Lawrence ^a   Jean Claude, Bertrand J ^b   Vasilescu, Daniela ^b   Mustafa, Amir ^b   Damian, Sorin ^b   Damian, Zoe ^b   Georges, Elias ^c   Liu, Zhi ^c   Batis, Gerald ^d   Leyland Jones, Brian ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NONE

Author keywords

adriamycin resistance; breast cancer; megestrol acetate; tamoxifen

Indexed keywords

COLCHICINE; DOXORUBICIN; DYE; GLYCOPROTEIN P; IODINE 125; MEGESTROL ACETATE; SULFORHODAMINE B; TAMOXIFEN; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; SENSITIZATION;

EID: 0030580037     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00456-X     Document Type: Article

References (33)

1. 1. Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP and Falkson HC, The Eastern Cooperative Oncology Group experience with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219-224, 1985.
2. 2. Muss HB, White DR, Richards F, Cooper RM, Stuart JJ, Jackson DV, Rhyne L and Spurr CL. Doxorubicin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42: 2141-2148, 1978.
3. 3. Nemoto T, Horton J, Simon R, Dao TL, Rosner D, Cunningham T, Sponzo R and Synderman M, Comparison of four combination chemotherapy programs in metastatic breast cancer. Cancer 49: 1988-1993, 1982.
4. 4. Vogel CL, Smalley RV, Raney M, Krauss S, Carpenter J, Velez-Garcia E, Fishkin E, Raab S, Moore MR and Stagg M, Randomized trial of cyclophosphamide, doxorubicin and 5-fluororacil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: A Southeastern Cancer Society group project. J Clin Oncol 2: 643-651, 1984.
5. 5. Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C and Rice MA, Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235-1244, 1982.
6. 6. Hoogstraten MD, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thipen T and Braine H, Combination chemotherapy and doxorubicin in patients with advanced breast cancer. Cancer 38: 13-20, 1976.
7. 7. Carmo-Pereira J, Costa FL and Henriques E, Chemotherapy of advanced breast cancer - A randomized trial of vincristine, doxorubicin and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP). Cancer 48: 1517-1521, 1981.
8. 8. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD and Chapman PJ, A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9: 2148-2152, 1991.
9. 9. Moscow JA and Cowan KH, Multidrug resistance. J Natl Cancer Inst 80: 14-20, 1988.
10. 10. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y, Increased accumulation of vincristine and doxorubicin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733, 1982.
11. 11. Slater LM, Sweet P, Stupecky M, Wetzel MW and Gupta S, Cyclosporine A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54: 235-238, 1986.
12. 12. Ramu A, Fuks Z, Gatt S and Glaubiger D, Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res 44: 144-148, 1984.
13. 13. Cornwell MM, Gottesman MM and Pastan I, Increased vinblastine binding to membrane vesicles from multidrug resistant KB cells. J Biol Chem 261: 7921-7928, 1986.
14. 14. Ramu A, Glaubiger D and Fuks Z, Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44: 4392-4395, 1984.
15. 15. DeGregorio MW, Ford JM, Benz CC and Wiebe VJ, Toremifene: Pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7: 1359-1364, 1989.
16. 16. Trump DL, Smith SC, Ellis PG, Rogers MP, Schold MP, Winer EP, Panella TJ, Jordan VC and Fine RL, High dose oral tamoxifen, a potential multidrug-resistance-reversal agent: A phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816, 1992.
17. 17. Yang C-PH, Depinho SG, Greenberger LM, Arceci RJ and Horwitz SB, Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of the gravid uterus. J Biol Chem 264: 782-789, 1989.
18. 18. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowan KH, Overexpression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986.
19. 19. Kramer R, Zakher J and Kim G, Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694-697, 1988.
20. 20. Vickers P, Dickson R, Shoemaker R and Cowan K, A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to anti-estrogens and hormone-independent tumor growth. Mol Endocrinol 2: 886-892, 1988.
21. 21. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR, New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
22. 22. Berenbaum MC, Letter to the Editor. Cancer Res 52: 4558-4559, 1992.
23. 23. Fairbanks G, Steck TL and Wallach DFH, Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 10: 2606-2617, 1971.
24. 24. Greenberger LM, Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J Biol Chem 268: 11417-11425, 1993.
25. 25. Safa AR, Mehta ND and Agresti M, Photoaffinity labelling of P-glycoprotein in multidrug resistant cells with photoreactive analogs of colchicine. Biochem Biophys Res Commun 162: 1402-1408, 1989.
26. 26. Bruno NA and Slate DL, Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. J Natl Cancer Inst 82: 419-424, 1990.
27. 27. Woods KE, Randolph JK and Gewirtz DA, Antagonism between tamoxifen and doxorubicin in the MCF-7 human breast tumor cell line. Biochem Pharmacol 47: 1449-1451, 1994.
28. 28. Fine RL, Sachs CW, Albers M and Williams A, Tamoxifen potentiates the cytotoxicity of vinblastine by increasing intracellular drug accumulation. Proc Am Assoc Cancer Res 32: 375, 1991.
29. 29. Wang L, Yang C-PH, Trial P, Horwitz SB and Casazza AM, Reversal of the multidrug resistance (MDR) phenotype with megesterol acetate (MA). Proc Am Assoc Cancer Res 32: 377, 1991.
30. 30. Wang L, Yang C-PH, Horwitz SB, Trial PA and Casazza AM, Reversal of the human multidrug-resistance phenotype with megestrol acetate. Cancer Chemother Pharmacol 34: 96-102, 1994.
31. 31. Daniel P, Gaskell SJ, Bishop H, Campbell C and Nicholson R, Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma. Eur J Cancer Clin Oncol 17: 1183-1189, 1981.
32. 32. DeGregorio MW, Wilbur BJ, Coronado E and Osborne CK, Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chemother Pharmacol 20: 316-318, 1987.
33. 33. Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B and Andreeff M, Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77: 818-825, 1991.